MPLN offers SP263 immunohistochemical testing for the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded tissue. PD-L1 expression level utilizing this clone has been associated with response to durvalumab (IMFINZI, AstraZeneca UK Limited). AstraZeneca recently gained FDA approval durvalumab and for its complementary diagnostic Ventana PD-L1.
Assessment of tumor PD-L1 protein levels may have prognostic and/or therapeutic significance in some cancer patients. Specifically, identifying PD-L1 expression on tumor cells may help determine which patients will most benefit from anti-PD-1/PD-L1 therapy.
The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody (VENTANA PD-L1 (SP263)) is a rabbit monoclonal primary antibody directed against the programmed deathligand1 (PD-L1) B7 homolog 1 (B7-H1, CD274). The antibody detects the extracellular domain of PD-L1 and produces membranous and/or cytoplasmic staining.
PD-1 by immunohistochemistry detects the immune regulatory molecule programmed death-1 (PD-1) and has utility in both hematopathology diagnostics and in cancer biology. The programmed death-1 (PD-1) protein is expressed by follicular helper T-cells, and is useful in the diagnosis of hematolymphoid malignancies such as angioimmunoblastic T-cell lymphoma (AITL). In addition, clinical evidence suggests that IHC staining of the PD-1/PD-L1 pathway may have prognostic and/or therapeutic significance in some cancer patients.
MPLN selected the Ventana SP263 antibody as it complements existing laboratory platform and automation and has a simple single numerical cutoff value making interpretation more robust.
Commenting is turned off for this post.Commenting is not available in this channel entry.